AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysis Alebund grants exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China to R1...
Hence then, the article about alebund pharmaceuticals announces collaboration and license agreement with r1 therapeutics for ap306 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306 )
Also on site :
- En medio de la crisis, el Gobierno de Cuba anuncia reformas económicas aunque persisten los obstáculos
- LA28 ticket registration nears deadline as first Olympic qualifiers emerge
- What do you need to vote in Illinois? What you can take into the ballot box with you